OncoMatch/Clinical Trials/NCT06730308
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Is NCT06730308 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Concurrent chemotherapy and Methylprednisolone for thymoma.
Treatment: Concurrent chemotherapy · Methylprednisolone — This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify